New drug combo for returning AITL lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of drugs (azacytidine plus CAOLD) for people with a specific type of T-cell lymphoma called AITL that has come back or not responded to previous treatment. The goal is to see if this treatment can work better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of angioimmunoblastic T-cell lymphoma (AITL), a specific type of T-cell lymphoma.
- You are 18 years or older.
- Your lymphoma has come back after treatment (relapsed) or did not respond to at least one prior treatment.
- Your blood cell counts are within certain limits (for example, your neutrophils are at least 1.5 billion/L, or lower if your bone marrow is involved).
- You do not have an active uncontrolled infection or other major unstable health problem.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (venetoclax plus CACAG chemotherapy) for people whose acute myeloid leukemia has come back or not responded to earlier treatments. The goal is to see if this combination can help control the leukemia.
This trial tests a combination of two medicines—azacitidine and a PD-1 inhibitor—for people with Hodgkin lymphoma that has returned or not responded to previous treatment. The aim is to see if this combination can help control the disease.
This trial tests a combination of five drugs (tislelizumab, cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone) for patients with angioimmunoblastic T-cell lymphoma (AITL) that has come back or not responded to previous treatment. The goal is to see if this combination can shrink tumors or stop the disease from growing.
This study tests a combination of three drugs (azacitidine, chidamide, and a PD-1 inhibitor) for T-cell lymphomas that have returned or stopped responding to previous treatment. The goal is to see if this combination can help shrink the cancer.
This trial tests a combination of five drugs for people newly diagnosed with a rare type of lymphoma called angioimmunoblastic T-cell lymphoma (AITL). The goal is to see if this treatment helps control the cancer.
This trial tests a combination of two drugs (a demethylating agent and venetoclax) to help prevent high-risk T-cell lymphoma or leukemia from coming back after a stem cell transplant. It is for patients who have certain risk factors for relapse.
Hear when a new Relapsed Peripheral T-Cell Lymphomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.